Comparative Pharmacology
Head-to-head clinical analysis: KYNMOBI versus NEUPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KYNMOBI versus NEUPRO.
KYNMOBI vs NEUPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apomorphine is a non-ergoline dopamine receptor agonist with high affinity for D4 and moderate affinity for D2, D3, D5, and D1 receptors. It also has affinity for serotonergic (5-HT1A, 5-HT2A, 5-HT2B) and adrenergic (α1, α2) receptors. It improves motor function in Parkinson disease by stimulating striatal dopamine receptors.
Rotigotine is a non-ergoline dopamine agonist with high affinity for dopamine D1, D2, D3, D4, and D5 receptors; also binds to serotonin 5-HT1A and alpha2-adrenergic receptors.
Sublingual film: 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg as a single dose for acute off episodes; may repeat once within 4 hours if inadequate response; maximum 30 mg per dose and 3 doses per day.
Apply transdermally once daily; initial dose 2 mg/24h, titrated weekly by 2 mg/24h up to 6 mg/24h, maximum 8 mg/24h.
None Documented
None Documented
The terminal elimination half-life of apomorphine is approximately 40 minutes. This short half-life necessitates continuous administration via subcutaneous infusion for sustained clinical effect.
Single dose: 5-7 hours (transdermal); steady state: 7-10 hours; effective half-life for dosing is 8 hours due to reservoir in skin
Apomorphine is predominantly metabolized in the liver. Renal excretion accounts for approximately 80% of the dose, with 10% excreted as unchanged drug and 70% as metabolites. Biliary/fecal excretion accounts for the remaining 20%.
Renal: 45% (metabolites), Fecal: 40% (metabolites), Biliary: 15%
Category C
Category C
Dopamine Agonist
Dopamine Agonist